Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim GmbH announced today that it has begun to enroll patients in the SPRING study. The SPRING study will be one of the largest racially and gender diverse international studies of highly ...
From: www.presseportal.de
tipranavir) in Diverse Group of Highly Treatment-Experienced ...
Posted by Ruslan Abuzant at 6:14 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment